The effect of bromocriptine on locomotor activity and cerebral catecholamines in rodents

The locomotor activity in mice induced by bromocriptine was suppressed by drugs inhibiting both dopaminergic and noradrenergic pre‐ and post‐synaptic actions. The onset of locomotor activity was preceded by a period of decreased activity which lengthened with increasing dose. Both increased and decreased turnover of noradrenaline and decreased turnover of dopamine was shown by measurement of the dopamine metabolites homovanillic acid, dihydroxyphenylacetic acid (DOPAC) and the noradrenaline metabolite MOPEG‐SO4 and following pretreatment of animals with α‐methyl‐p‐tyrosine. The increased activity caused by bromocriptine did not correlate with a consistent biochemical change, but the period of behavioural suppression appeared to be associated with an increased noradrenaline turnover. Bromocriptine potently inhibited the noradrenaline‐stimulated adenylate cyclase system from mouse limbic forebrain suggesting that the increased in vivo turnover of noradrenaline may be due to a post‐synaptic receptor blockade. The involvement of cerebral dopamine receptors was substantiated by the ability of bromocriptine to displace [3H]haloperidol from binding sites in rat striatal preparations. The findings are interpreted as indicating a complex involvement of both noradrenaline and dopamine pre‐and post‐synaptic components in the locomotor activity produced by bromocriptine, possibly due to the involvement of a partial agonist action or an active metabolite.

[1]  K. E. Moore,et al.  Mesolimbic dopaminergic neurones in the rotational model of nigrostriatal function , 1976, Nature.

[2]  G. Pegrum,et al.  Pretreatment with antilymphocyte globulin and donor cells on graft prolongation in an experimental model and some observations on graft-versus-host reaction. , 1976, Postgraduate medical journal.

[3]  C. Pycock,et al.  Ergot alkaloids as dopamine agonists: comparison in two rodent models. , 1976, European journal of pharmacology.

[4]  T. Hökfelt,et al.  Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons , 1973, The Journal of pharmacy and pharmacology.

[5]  K Fuxe,et al.  Evidence for a central noradrenaline receptor stimulation by clonidine. , 1970, Life sciences.

[6]  D. Calne,et al.  Bromocriptine in Parkinsonism , 1974, British medical journal.

[7]  L. Bigelow,et al.  The fluorometric estimation of epinephrine and norepinephrine: an improved modification of the trihydroxyindole method. , 1968, Analytical biochemistry.

[8]  D. Sharman,et al.  STUDIES ON THE METABOLISM OF CATECHOLAMINES IN THE CENTRAL NERVOUS SYSTEM OF THE MOUSE , 1974, British journal of pharmacology.

[9]  J. Korf,et al.  Regional rat brain levels of 3,4-dihydroxyphenylacetic acid and homovanillic acid: concurrent fluorometric measurement and influence of drugs. , 1976, European journal of pharmacology.

[10]  C. Marsden,et al.  The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or α-methyl-p-tyrosine pre-treated mice , 1976, Pharmacology Biochemistry and Behavior.

[11]  A. M. Johnson,et al.  STIMULANT PROPERTIES OF BROMOCRIPTINE ON CENTRAL DOPAMINE RECEPTORS IN COMPARISON TO APOMORPHINE, (+)‐AMPHETAMINE AND l‐DOPA , 1976, British journal of pharmacology.

[12]  A. Grey,et al.  A Conformational Study of Lysergic Acid and iso-Lysergic Acid Dialkylamides by Proton Magnetic Resonance Spectroscopy , 1972 .

[13]  C. Chothia,et al.  Molecular Structure of LSD , 1972, Science.

[14]  D. Howlett,et al.  Urinary 3‐methoxy‐4‐hydroxyphenylglycol production in mice and rats following intraventricular 6‐hydroxydopamine , 1975, The Journal of pharmacy and pharmacology.

[15]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[16]  J. Blumberg,et al.  Blockade by pimozide of a noradrenaline sensitive adenylate cyclase in the limbic forebrain: possible role of limbic noradrenergic mechanisms in the mode of action of antipsychotics , 1975, The Journal of pharmacy and pharmacology.

[17]  I. Creese,et al.  The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states. , 1975, Life sciences.

[18]  J. Leysen,et al.  Differential distribution of opiate and neuroleptic receptors and dopamine-sensitive adenylate cyclase in rat brain. , 1977, Life sciences.

[19]  S. Fahn,et al.  Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover , 1976, The Journal of pharmacy and pharmacology.

[20]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[21]  A. Cools,et al.  The nucleus accumbens of rats and dopaminergic mechanisms regulating locomotor behaviour , 1976, Neuroscience Letters.

[22]  P. Leigh,et al.  Treatment of parkinsonism with bromocriptine. , 1974, Lancet.

[23]  J. Maj,et al.  The effect of clonidine on locomotor activity in mice. , 1972, Life sciences. Pt. 1: Physiology and pharmacology.

[24]  S. Fahn,et al.  Increase in brain serotonin produced by bromocryptine , 1975, Neuroscience Letters.

[25]  J. Meek,et al.  Fluorometric estimation of 4‐hydroxy‐3‐methoxyphenylethyleneglycol sulphate in brain , 1972, British journal of pharmacology.

[26]  C. Marsden,et al.  Noradrenaline-sensitive adenylate cyclase in slices of mouse limbic forebrain: characterisation and effect of dopaminergic agonists. , 1977, Biochemical pharmacology.

[27]  C. Marsden,et al.  Bromocriptine treatment in Parkinson's disease. , 1976, Journal of neurology, neurosurgery, and psychiatry.

[28]  C. Atack The determination of dopamine by a modification of the dihydroxyindole fluorimetric assay , 1973, British journal of pharmacology.

[29]  P. Spano,et al.  Effects of bromocriptine on central dopaminergic receptors. , 1976, Life sciences.